Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 17 (Search time: 0.002 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2009
Dasatinib or high-dose Imatinib for chronic-phase chronic myeloid leukemia resistant to Imatinib at a dose of 400 to 600 milligrams daily. Two-year follow-up of a randomized phase 2 study (START-R)
Kantarjian, H.
;
Pasquini, R.
;
Levy, V.
;
Jootar, S.
;
Holowiecki, J.
;
Hamerschlak, N.
;
Hughes, T.
;
Bleickardt, E.
;
Dejardin, D.
;
Cortes, J.
;
Shah, N.
2009
Dasatinib treatment for Philadelphia chromosome-positive Leukemias: practical considerations
Khoury, H.
;
Guilhot, F.
;
Hughes, T.
;
Kim, D.
;
Cortes, J.
2014
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib
Olshen, A.
;
Tang, M.
;
Cortes, J.
;
Gonen, M.
;
Hughes, T.
;
Branford, S.
;
Quintás-Cardama, A.
;
Michor, F.
2016
Chronic myeloid leukemia: reminiscences and dreams
Mughal, T.
;
Radich, J.
;
Deininger, M.
;
Apperley, J.
;
Hughes, T.
;
Harrison, C.
;
Gambacorti-Passerini, C.
;
Saglio, G.
;
Cortes, J.
;
Daley, G.
2016
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
Deininger, M.
;
Hodgson, J.
;
Shah, N.
;
Cortes, J.
;
Kim, D.
;
Nicolini, F.
;
Talpaz, M.
;
Baccarani, M.
;
Müller, M.
;
Li, J.
;
Parker, W.
;
Lustgarten, S.
;
Clackson, T.
;
Haluska, F.
;
Guilhot, F.
;
Kantarjian, H.
;
Soverini, S.
;
Hochhaus, A.
;
Hughes, T.
;
Rivera, V.
;
et al.
2008
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
le Coutre, P.
;
Ottmann, O.
;
Giles, F.
;
Kim, D.
;
Cortes, J.
;
Gattermann, N.
;
Apperley, J.
;
Larson, R.
;
Abruzzese, E.
;
O'Brien, S.
;
Kuliczkowski, K.
;
Hochhaus, A.
;
Mahon, F.
;
Saglio, G.
;
Gobbi, M.
;
Kwong, Y.
;
Baccarani, M.
;
Hughes, T.
;
Martinelli, G.
;
Radich, J.
;
et al.
2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M.
;
Deininger, M.
;
Rosti, G.
;
Hochhaus, A.
;
Soverini, S.
;
Apperley, J.
;
Cervantes, F.
;
Clark, R.
;
Cortes, J.
;
Guilhot, F.
;
Hansen-Hjorth, H.
;
Hughes, T.
;
Kantarjian, H.
;
Kim, D.
;
Larson, R.
;
Lipton, J.
;
Mahon, F.
;
Martinelli, G.
;
Mayer, J.
;
Muller, M.
;
et al.
2008
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia
Giles, F.
;
DeAngelo, D.
;
Baccarani, M.
;
Deininger, M.
;
Guilhot, F.
;
Hughes, T.
;
Radich, J.
;
Ottmann, O.
;
Cortes, J.
2009
Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phase
Hughes, T.
;
Saglio, G.
;
Branford, S.
;
Soverini, S.
;
Kim, J.
;
Muller, M.
;
Martinelli, G.
;
Cortes, J.
;
Beppu, L.
;
Gottardi, E.
;
Dongho, K.
;
Erben, P.
;
Shou, Y.
;
Haque, A.
;
Gallagher, N.
;
Radich, J.
;
Hochhaus, A.
2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Muller, M.
;
Cortes, J.
;
Kim, D.
;
Druker, B.
;
Erben, P.
;
Pasquini, R.
;
Branford, S.
;
Hughes, T.
;
Radich, J.
;
Ploughman, L.
;
Mukhopadhyay, J.
;
Hochhaus, A.
Discover
Author
9
Hochhaus, A.
8
Baccarani, M.
8
Kantarjian, H.
8
Kim, D.
8
Radich, J.
7
Guilhot, F.
5
Apperley, J.
5
Branford, S.
5
Deininger, M.
5
Larson, R.
.
next >
Subject
11
Humans
10
Pyrimidines
9
Benzamides
9
Leukemia, Myelogenous, Chronic, B...
9
Piperazines
8
Antineoplastic Agents
8
Imatinib Mesylate
8
Treatment Outcome
7
Protein Kinase Inhibitors
6
Fusion Proteins, bcr-abl
.
next >
Date issued
2
2016
2
2014
1
2013
1
2012
3
2011
6
2009
2
2008